key: cord-0722345-mpd4v6jl authors: Günther, Sebastian; Reinke, Patrick Y. A.; Oberthuer, Dominik; Yefanov, Oleksandr; Ginn, Helen; Meier, Susanne; Lane, Thomas J.; Lorenzen, Kristina; Gelisio, Luca; Brehm, Wolfgang; Dunkel, Illona; Domaracky, Martin; Saouane, Sofiane; Lieske, Julia; Ehrt, Christiane; Koua, Faisal; Tolstikova, Alexandra; White, Thomas A.; Groessler, Michael; Fleckenstein, Holger; Trost, Fabian; Galchenkova, Marina; Gevorkov, Yaroslav; Li, Chufeng; Awel, Salah; Peck, Ariana; Xavier, P. Lourdu; Barthelmess, Miriam; Schlünzen, Frank; Werner, Nadine; Andaleeb, Hina; Ullah, Najeeb; Falke, Sven; Franca, Bruno Alves; Schwinzer, Martin; Brognaro, Hévila; Seychell, Brandon; Gieseler, Henry; Melo, Diogo; Zaitsev-Doyle, Jo J.; Norton-Baker, Brenna; Knoska, Juraj; Esperanza, Gisel; Mashhour, Aida Rahmani; Guicking, Filip; Hennicke, Vincent; Fischer, Pontus; Rogers, Cromarte; Monteiro, Diana C. F.; Hakanpää, Johanna; Meyer, Jan; Noei, Heshmat; Gribbon, Phil; Ellinger, Bernhard; Kuzikov, Maria; Wolf, Markus; Zhang, Linlin; Sun, Xinyuanyuan; Pletzer-Zelgert, Jonathan; Wollenhaupt, Jan; Feiler, Christian; Weiss, Manfred; Schulz, Eike-Christian; Mehrabi, Pedram; Schmidt, Christina; Schubert, Robin; Han, Huijong; Krichel, Boris; Fernández-García, Yaiza; Escudero-Pérez, Beatriz; Günther, Stephan; Turk, Dusan; Uetrecht, Charlotte; Beck, Tobias; Tidow, Henning; Chari, Ashwin; Zaliani, Andrea; Rarey, Matthias; Cox, Russell; Hilgenfeld, Rolf; Chapman, Henry N.; Pearson, Arwen R.; Betzel, Christian; Meents, Alke title: Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease date: 2020-05-04 journal: bioRxiv DOI: 10.1101/2020.05.02.043554 sha: 2e37b09cf79249fd935ec261e7be62f8971d3323 doc_id: 722345 cord_uid: mpd4v6jl Here we present the crystal structure of SARS-CoV-2 main protease (Mpro) covalently bound to 2-methyl-1-tetralone. This complex was obtained by co-crystallization of Mpro with HEAT (2-(((4-hydroxyphenethyl)amino)methyl)-3,4-dihydronaphthalen-1(2H)-one) in the framework of a large X-ray crystallographic screening project of Mpro against a drug repurposing library, consisting of 5632 approved drugs or compounds in clinical phase trials. Further investigations showed that HEAT is cleaved by Mpro in an E1cB-like reaction mechanism into 2-methylene-1-tetralone and tyramine. The catalytic Cys145 subsequently binds covalently in a Michael addition to the methylene carbon atom of 2-methylene-1-tetralone. According to this postulated model HEAT is acting in a pro-drug-like fashion. It is metabolized by Mpro, followed by covalent binding of one metabolite to the active site. The structure of the covalent adduct elucidated in this study opens up a new path for developing non-peptidic inhibitors. The pandemic disease caused by the coronavirus SARS-CoV-2 is an international health challenge and there is an immediate need for the identification of drugs for treatment of SARS-CoV-2 infections. Infection of host cells critically depends on several molecular factors from both the host and virus (1, 2) . Coronaviruses are RNA-viruses with a genome of around 30 kbp. The viral gene essential for the replication of the virus is expressed as polyprotein that must be broken into functional subunits for replication and transcription activity (1) . This proteolytic cleavage is primarily accomplished by the main protease (M pro ), also known as the 3C-like protease 3CL pro . M pro cleaves the viral polyprotein at eleven sites. The core cleavage motif is Leu-Gln(Ser/Ala/Gly) (1) . M pro possesses a chymotrypsin-like fold amended by a C-terminal helical domain and harbors a catalytic dyad comprising Cys145 and His41 (1) . The active site is located in a cleft between the two N-terminal domains of the three domain structure of the monomer, while the C-terminal helical domain is involved in regulation of dimerization of the enzyme with a dimerization constant of 2.5 µM (1) . Due to its central involvement in virus replication M pro is well established as a prime target for antiviral compounds that can tackle coronavirus infections (3) . Indeed first studies confirm the potential of targeting M pro for inhibition of virus replication (1, 2) . In order to identify further potential drug candidates with an inhibitory effect on M pro we screened the "Fraunhofer IME Repurposing Collection" (4), consisting of 5632 individual compounds against M pro by means of high-throughput X-ray crystallography. This compound collection is based on the BROAD institute repurposing library (5) . In contrast to crystallographic screening campaigns with small molecules ("fragment screening") (6), our library contains compounds that are chemically more complex and of larger molecular mass. As M pro crystals possess a low solvent content of only 38% (1) with narrow solvent channels that could impede larger molecules from diffusing into the active site in soaking experiments, we co-crystallized M pro with the individual compounds instead of soaking pre-grown M pro crystals in compoundcontaining solutions. Crystals typically appeared within 2 days and were then submitted to single crystal X-ray structure determination (see Methods). From the resulting X-ray structures, several compounds were identified in complex with M pro . Among these was BE-2254 (HEAT, 2-(((4-hydroxyphenethyl)amino)methyl)-3,4-dihydronaphthalen-1(2H)-one), where a well resolved electron-density was observed in the active site of the M pro crystal structure. This electron-density can be well modeled as 2-methyl-1-tetralone (METT) covalently bound to the sulfur atom of Cys145, thereby blocking access to the active site of M pro and occupying the P1 site of the protease. 2-Methyl-1-tetralone is potentially a breakdown product of the parent compound HEAT included in the co-crystallization experiment. HEAT was first synthesized by Hansen at Beiersdorf AG (7) . It exists in an equilibrium between two enantiomers between which it transitions via ketoenol tautomerism (8) . Investigations by several groups found it to be a competitive α-adrenoreceptor antagonist in vitro and in vivo with lower affinity to the α-subtype and residual affinity to dopaminergic and serotonergic receptors (9) . Here we present the crystal structure of M pro with 2-methyl-1-tetralone (METT) covalently bound to the active site to 1.8 Å resolution. To further support this observation and to understand the underlying mechanism of HEAT fragmentation by M pro and its subsequent covalent binding to the active site, we conducted complementary native and small molecule mass spectrometry and computational docking studies. On the basis of these results we propose a reaction mechanism and provide an outlook for the application of HEAT as a starting point for potential drug development to treat SARS-CoV-2 infections. The overall structure of the SARS-CoV-2 main protease (M pro ) with bound METT as obtained in our X-ray diffraction experiment is shown in figure 1 (table 1). It possesses the same overall structural features as previously described (1, 2) . A closer view of the active site reveals clear unoccupied electron-density for a small molecule covalently bound to the catalytic Cys145 which could be well modeled as METT (figure 1B). The chemical structures of the parent compound HEAT and the observed cleavage product METT bound to M Pro are illustrated in figure 1C and D, respectively, clearly showing the relationship between the two molecules. This observation suggests METT to be a breakdown product of HEAT, with tyramine (TY) as the complementary product ( figure 1E ). To confirm the cleavage of HEAT by M pro and subsequent covalent binding of METT to M pro , native mass spectrometry (MS) experiments were performed (10) . In a control experiment without the addition of HEAT we observe a high intensity peak envelope corresponding to the expected mass of the M pro dimer (67,599 +/-5 Da, charge states +14 to +16). The monomer is also visible with lower intensity (33,795 +/-2 Da, charge states +9 to +11) (figure 2A). Next M pro was incubated with HEAT at a molar ratio of 1:10 (M pro :HEAT) overnight. After incubation of M pro with HEAT two additional peak envelopes can be observed in the high mass range (figure 2B). Their assigned masses correspond to the M pro dimer alone or plus one and two METT molecules (67,593/67,774/67,955 Da). The corresponding stoichiometry of M pro dimer without or either one or two bound METT was approximately 4:5:1. Additionally peaks from monomeric M pro bound to one METT molecule and unmodified M pro are also observed. The expected ion of intact HEAT with 296 Da (MH + ) is observed in the low mass range (suppl. fig. 1 ). The reaction product METT is not observed as it is too small to be detected with the instrument settings used for these measurements. To probe the chemical interaction between M pro and HEAT, CID-MS/MS was performed by separating a molecular ion precursor (+15, dimer) in the quadrupole of the mass spectrometer and triggering its dissociation in a collision cell (see Methods). The dimer dissociated into low-and high-charge monomeric molecular ions. METT was observed to still be bound to the highcharge ions (suppl. figure 1) . The ratio of the dissociated monomer in the unbound to bound state was roughly 5:4. The binding of the reactive group to the dissociated molecule indicates a strong interaction between M pro and METT, as would be expected for a covalent bond. Furthermore, only one METT per monomer is detected which suggests that the interaction is sitespecific. Understanding of the underlying reaction mechanism requires knowledge about the initial binding of HEAT to M pro which was not observed in the X-ray diffraction experiment. To obtain information on the initial binding state of HEAT to M pro , computational docking studies were employed using JAMDA and HYDE (11) (figure 3). We visually inspected multiple proposed noncovalent binding modes which might help to reveal the possible reaction mechanism. The keto form of HEAT (figure 3A) is found to occupy pockets P1 and P2 with a carbon-sulfur distance of 3.4 Å. HEAT forms a hydrogen bond to His163 in the active site via the carbonyl oxygen atom, a weak hydrogen bond to Cys145 via its secondary amine, and a T-stacking interaction to His41. The enol form (figure 3B) seems to be more stably bound to the active site, forming not only the two aforementioned hydrogen bonds, but also a hydrogen bond to Cys44 via its phenol moiety. Additionally, a pi-pi stacking interaction between His41 and the phenol moiety can be observed in this predicted binding mode. Moreover, the carbon-sulfur distance of 3.5 Å for the enol form of HEAT to Cys145 is well within the acceptable range for covalent bond formation. This non-covalent binding mode corresponds well to the experimentally determined binding mode of METT which occupies the S1 pocket ( figure 3C) . Additionally, the leaving group of the molecule is situated in the S2 pocket and is engaged in a weak pi-pi stacking interaction with His41 and a weak hydrogen bond to Cys44. We hypothesize that HEAT initially binds non-covalently to the protease and is converted to the corresponding enol form prior to the formation of the α,β-unsaturated ketone. This process might be catalyzed by residues His163 and Cys145, which are engaged in hydrogen bonds to the product METT as well as the proposed non-covalently bound keto-and enol-form of HEAT. Due to the covalent binding to the active-site Cys145, we expected an inhibitory effect on the enzyme function and thus virus replication. Combining all experimental and computational results allows us to propose a plausible, albeit highly unusual, reaction mechanism. M pro is a cysteine protease possessing the conserved reactive center dyad Cys145 and His41, which together catalyze the sequence-specific hydrolysis of peptide bonds, vital for SARS-CoV-2 replication. We propose a similar mechanism for the cleavage of the drug HEAT, leading to a suicide reaction of the protease, which terminates in a covalent thioether bond between Cys145 and METT ( figure 4) . As initiation the tetralone carbonyl is activated by His163, forming an enol. The thiolate of Cys145 could serve as base, removing the hydrogen of the β-carbon and forming the enol. After enol-oxygen deprotonation by His163, an unimolecular conjugate base elimination (E1cB)-like mechanism expels the protonated tyramine amine, forming 2-methylen-1-tetralone in the active site. In a subsequent step this highly reactive intermediate reacts in a Michael addition, where the thiolate of Cys145 attacks the ,-unsaturated 2methylen-1-tetralone, forming a thioether bond resulting in covalently bound METT. This final reaction state was confirmed by X-ray crystallography to a resolution of 1.8 Å. As evident in our LC-MS analysis some METT can react with DTT and it is not yet clear whether this occurs within the active site or spontaneously in solution. Proposed reaction mechanism of HEAT with M pro . HEAT exists in equilibrium between a keto-(A) and enol-(B) form via tautomerism. The catalytic center bound enol form of HEAT eliminates the tyramine group, leaving 2-methylene-1-tetralone in the active site (C). This is attacked by the thiol of Cys145, forming the observed covalent thioether bond (D). This enol is again in equilibrium with the keto-form, observed in the X-ray structure (E). The current pandemic of SARS-CoV-2 and also the earlier epidemics caused by SARS-CoV and MERS-CoV revealed the risk posed by coronaviruses and stressed the need for pan-coronavirus antiviral drugs to be better prepared for future outbreaks. M pro is highly conserved across coronaviruses (12) (suppl. figure 3) . The active site residues His41 and Cys145 are strictly conserved. Furthermore, in our structure METT binding is stabilized by a hydrogen bond to His163 as well as by van der Waals interactions with the backbone of the oxyanion hole formed by residues Leu141 and Asn142 and neighboring Phe140. These residues are all essential for the protease activity of M pro and thus are conserved as well. Further experiments to investigate the influence of HEAT on the activity of other coronaviruses need to be conducted to confirm the potential of developing HEAT as a pan-coronavirus inhibitor. Currently most structurally well described SARS-CoV-2 M pro inhibitors are rationally designed peptidomimetic or peptide-based inhibitors (1, 2, 13, 14) . However, some structures of non-peptidic inhibitors were recently reported. For example Baicalein is a natural product derived from traditional Chinese medicine (15) . It is non-covalently bound in the active site of M pro . In contrast the antineoplastic drug carmofur is converted by M pro and its lipophilic hexamethylcarbamate moiety remains covalently bound to Cys145 (16), likely through a mechanism reminiscent of hydrolyzing a peptide substrate. Chemically the mechanism of reaction of carmofur with M pro is different from the one we observe for HEAT. In conclusion we have discovered that the alpha adrenergic antagonist HEAT is metabolized by and covalently bound to the active site of SARS-CoV-2 M pro . Further evaluation of the antiviral activity of HEAT is required, as in a first high throughput screen of the same repurposing library it did not show any significant antiviral activity (4) . In spite of this, the complex between METT and M pro can be considered a starting point for future drug design efforts. Chemical modifications of the molecule might help to endow it with pharmacologically relevant inhibitory activity and to develop HEAT towards a viable drug option. The obtained results also strongly highlight that drug discovery investigations to treat SARS-CoV-2 should not only focus on traditional and conservative approaches aiming to identify substrate-analogue inhibitors, but should also include the identification and discovery of pro-drug compounds that could act as suicide drugs (17, 18) . This approach is based on the simple but effective idea of a classical pro-drug, which needs to be metabolized first before becoming toxic for the infecting agent, in this case the virus SARS-Cov-2 via deactivation of M pro . In this context and according to our postulated model, HEAT can be considered as a pro-drug as well as suicide drug which binds first to the active site of M pro , where it is cleaved in an E1cB-like reaction mechanism into 2methylene-1-tetralone and tyramine. The Cys145 sulfur subsequently binds covalently in a Michael addition to the methylene carbon atom of 2-methylene-1-tetralone thereby blocking the active site and inactivating M pro . Methods M pro crystallization. The protein was overexpressed in E. coli and purified for subsequent crystallization according to previously published protocols (1). Cocrystallization with the compounds was achieved by equilibrating a 6.25 mg/ml protein solution in 20 mM HEPES buffer (pH 7.8) containing 1 mM DTT, 1 mM EDTA, and 150 mM NaCl against a reservoir solution of 100 mM MIB, pH 7.5, containing 25% w/w PEG 1500 and 5% v/v DMSO. Prior to crystallization compound solutions in DMSO were dried onto the wells of SwissCI 96-well plates. To obtain well-diffracting crystals in a reproducible way seeding was applied for crystal growth. Crystals appeared within a few hours and reached their final size after 2 -3 days. Crystals were manually harvested and flashfrozen in liquid nitrogen for subsequent X-ray diffraction data collection. X-ray data collection and processing. X-ray data were collected at beamline P11 at the synchrotron radiation facility PETRA III at DESY in Hamburg (19) . Data were collected at an X-ray energy of 12 keV. Using the P11 sample changing robot data collection time was 3 minutes for a full 200 degree rotation dataset, including sample exchange. Data analysis was carried out using XDS (20) , COOT (21) , PHENIX (22) , and PanDDA (23) , in addition to some bespoke software tools. Chemical restraints for the bound compound were generated from SMILES using phenix.elbow (24) and compared with results from acedrg (25) and grade (26) . The fully refined model and structure factors were deposited in the PDB with accession code 6YNQ. The distribution of protein residues over the Ramachandran plot was 97.04/2.63/0.33% (favored/allowed/outliers). Mass-spectrometric analysis of compound binding. M pro samples were prepared for native MS measurements by buffer-exchange into ESI compatible solutions. M pro was buffer exchanged into 300 mM NH 4 OAc, pH 7.5 by five cycles of centrifugal gel filtration (Vivaspin columns, 30.000 MWCO, Sartorius). M pro (250 µM, 300 mM NH 4 OAc, pH 7.5) was incubated with HEAT (2.5 mM in DMSO) for 20 h and diluted 1:20. Nano ESI capillaries were pulled in-house from borosilicate capillaries (1.2 mm outer diameter, 0.68 mm inner diameter, filament, World Precision Instruments) with a micropipette puller (P-1000, Sutter instruments) using a squared box filament (2.5 × 2.5 mm 2 , Sutter Instruments) in a two-step program. Subsequently capillaries were gold-coated using a sputter coater (Q150R, Quorum Technologies) with 40 mA, 200 s, tooling factor 2.3 and end bleed vacuum of 8×10 −2 mbar argon. Native MS was performed using an electrospray quadrupole time-of-flight (ESI-Q-TOF) instrument (Q-TOF2, Micromass/Waters, MS Vision) modified for higher masses (27) . Samples were ionized in positive ion mode with voltages applied at the capillary of 1300 V and at the cone of 130 V. The pressure in the source region was kept at 10 mbar throughout all native MS experiments. For desolvation and dissociation, the pressure in the collision cell was adjusted to 1.8×10 -2 mbar argon. Native-like spectra were obtained at an accelerating voltage of 30-100 V, while for collision-induced dissociation these voltages were increased to 150-170 V. In ESI-MS overview spectra, the quadrupole profile was 1-10,000 m/z. In tandem MS, for precursor selection, LMres and HMres were adjusted at 50 V collisional voltage until a single peak was recorded, and then dissociation was induced. To calibrate raw data, CsI (25 mg/ml) spectra were acquired and calibration was carried out with MassLynx (Waters) software. Data were analysed using MassLynx (Waters). Small-molecule mass spectrometry. Analytical LC-MS data were obtained using a Waters Alliance 2795-HT LC-MS system equipped with a Phenomenex Kinetex column (2.6 μm, C 18 , 100 Å, 4.6 x 100 mm 2 ) and a Phenomenex Security Guard precolumn (Luna, C5, 300 Å) at a flow rate of 1 mL/min at 30 ˚C. Detection was carried out by a diode array detector (Waters 2998) in the range 210 to 600 nm together with a Waters Quatro-Micro mass detector, operating simultaneously in ES + and ES − modes between 100 and 1000 m/z. Solvents were: A, HPLC grade H 2 O containing 0.05% formic acid; B, HPLC grade CH 3 CN containing 0.045% formic acid. The gradient was as follows: 0 min, 10% B; 10 min, 90% B; 12 min, 90% B; 13 min, 10% B; 15 min, 10% B. Samples (20 µl) were made up in a mixture of buffer and CH 3 CN between 10 and 1000 µg/mL. Enzyme assays were terminated by addition of an equivalent volume of CH 3 CN. Protein was removed by centrifugation and reaction components were directly injected. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Structure of M pro from COVID-19 virus and discovery of its inhibitors. Nature From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection The Drug Repurposing Hub: a next-generation drug library and information resource Six Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study DE1913199C3 HEAT: Fifty percent of the ligand can bind to the alpha1-adrenoceptors with extremely high affinity The Receptors Advances in Virus 105 of Complementary Strategies to Understand Virus Structure and Function A consistent description of HYdrogen bond and DEhydration energies in protein-ligand complexes: methods behind the HYDE scoring function Virus-encoded proteinases and proteolytic processing in the Nidovirales A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main protease including SARS-CoV-2 (COVID-19) Structurebased design of antiviral drug candidates targeting the SARS-CoV-2 main protease Structure of ThiM from Vitamin B1 biosynthetic pathway of Staphylococcus aureus -Insights into a novel pro-drug approach addressing MRSA infections MRSA Infections: From Classical Treatment to Suicide Drugs Status of the crystallography beamlines at PETRA III Features and development of Coot PHENIX: a comprehensive Python-based system for macromolecular structure solution A multicrystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation AceDRG: a stereochemical description generator for ligands Improving the Performance of a Quadrupole Timeof-Flight Instrument for Macromolecular Mass Spectrometry Author list Oleksandr Yefanov (1) Salah Awel (1) , Ariana Peck (11) Gisel Esperanza (1) Xinyuanyuan Sun Arwen R. Pearson (3,4) , Christian Betzel (3,13 , and Alke Meents Photon Science Vision Systems Max Planck Institute for the Structure and Dynamics of Matter Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), screening port Dynamics of Viral Structures, Heinrich-Pette-Institut, Leibniz-Institut für Experimentelle Virologie Chemistry and Biology of Proteins (CIPKEBIP) We explicitly thank all people who are not included on the author list, in particular those responsible for the PETRA III machine operation, and all other DESY staff who are making this joint effort possible. This research was supported in part through the Maxwell computational resources operated at Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany, and by the Max Planck Society, the Center for ultrafast imaging and the Joachim Herz Foundation (Biomedical Physics of Infection). Conserved residues are depicted in bold. Active site residues His41 and Cys145 are highlighted in black box. Also His163 forming a hydrogen bond to METT is conserved.